AOD-9604 10MG

The mechanism of action of AOD9604 centers on the regulation of lipid metabolism through a signaling cascade that is distinct from the growth-promoting pathways activated by full-length hGH. The key pathways are:

1. Beta-3 Adrenergic Receptor (β3-AR) Activation

In murine adipose tissue, the lipolytic effects of AOD9604 are critically dependent on functional beta-3 adrenergic receptors (β3-AR). Studies using β3-AR knockout mice demonstrated a complete abolition of AOD9604-induced lipolysis, confirming the receptor as an essential mediator [1]. In obese (ob/ob) mice, chronic research application with AOD9604 at 500 µg/kg/day i.p. for 14 days resulted in significant upregulation of β3-AR mRNA expression in white adipose tissue, effectively restoring lipolytic sensitivity that is typically blunted in the obese phenotype [1][10].

2. cAMP / Hormone-Sensitive Lipase (HSL) Pathway

Activation of β3-AR by AOD9604 stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL), the rate-limiting enzyme in triglyceride hydrolysis. This cascade promotes the breakdown of stored triglycerides into free fatty acids and glycerol (lipolysis) [2][11].

3. Inhibition of Acetyl-CoA Carboxylase (ACC) / Anti-Lipogenesis

Concurrently, AOD9604 inhibits acetyl-CoA carboxylase (ACC), the enzyme that catalyzes the first committed step in de novo fatty acid synthesis (lipogenesis). By suppressing ACC activity, AOD9604 reduces the conversion of acetyl-CoA to malonyl-CoA, thereby inhibiting new fat formation [2][12]. This dual action—stimulating fat breakdown while inhibiting fat synthesis—accounts for the net reduction in adipose tissue mass observed in preclinical models.

4. Why AOD9604 Does NOT Activate IGF-1 or the hGH Receptor

A critical distinction of AOD9604 from full-length hGH is its inability to activate the growth hormone receptor (GHR). Full-length hGH binds two GHR molecules (receptor dimerization), triggering the JAK2/STAT5 signaling cascade that stimulates hepatic production of Insulin-like Growth Factor 1 (IGF-1) [13]. Because AOD9604 represents only the C-terminal tail of hGH (residues 177–191), it lacks the structural domains (helices A and B) required for high-affinity GHR binding and dimerization [8][14]. Consequently, AOD9604 does not:

• Elevate serum IGF-1 levels [3][15]
• Stimulate cell proliferation (no mitogenic activity) [8]
• Induce insulin resistance or hyperglycemia [2][16]

This selectivity for metabolic effects without growth-promoting reported observations in study populations was a key design objective in the development of AOD9604 [3].

AOD9604 was originally developed as a potential anti-obesity experimental. In preclinical studies, the peptide demonstrated significant effects on body composition:

• ob/ob Mouse Model: Chronic research application with AOD9604 at 500 µg/kg/day i.p. for 14 days produced an average body weight reduction of ~8.1 g (~5.5%) compared to saline-treated controls, without any change in food intake, blood glucose, or serum IGF-1 [1][2].
• Zucker Rat Model: In obese Zucker (fa/fa) rats, oral administration of AOD9604 at 200–600 µg/kg/day for 18 days resulted in a dose-dependent reduction in body fat mass with no effects on lean body mass, demonstrating selectivity for adipose tissue [11][12].
• Fat Oxidation: Metabolic chamber studies showed a 50–60% increase in fat oxidation rate in AOD9604-treated animals versus controls, as measured by respiratory quotient (RQ) shifts [2].

Despite these promising preclinical results, a large randomized Phase 2b clinical trial (n=536, 24 weeks, oral dosing 1–25 mg/day) failed to demonstrate statistically significant weight loss compared to placebo in humans, leading to the termination of the obesity development program by Metabolic Pharmaceuticals in 2007 [16][17].

Regenerative research compound (Cartilage & Musculoskeletal Repair)

AOD9604 has attracted significant interest in the field of musculoskeletal regeneration, particularly for cartilage repair in osteoarthritis (OA):

• Rabbit OA Model (Kwon & Park, 2015): In a collagenase-induced OA model, intra-articular injection of AOD9604 alone significantly improved gross morphological scores (scale 0–4) from a mean of 3.4 (severe damage) to 1.6 (mild damage) at 8 weeks. When combined with hyaluronic acid (HA), scores improved further to 0.8 (near-normal). Histopathological analysis (Mankin scoring system) confirmed enhanced proteoglycan staining and restored cartilage surface regularity in research application groups [5].
• Chondrocyte Proliferation: In vitro studies suggest AOD9604 may enhance chondrocyte proliferation and extracellular matrix (ECM) synthesis, although the precise molecular pathway remains under investigation [6].
• Synergistic Combinations: AOD9604 is frequently studied in combination with BPC-157 and HA for potential synergistic tissue-repair effects [6][18].

Influenza Research (LAT8881)

Under the designation LAT8881, AOD9604 has been evaluated by Lateral Pharma Pty Ltd for host-protective properties against severe influenza A infection. Preclinical data suggests potential immunomodulatory effects [7].